250 related articles for article (PubMed ID: 31502015)
1. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
2. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.
Gabr A; Ranganathan S; Mouli SK; Riaz A; Gates VL; Kulik L; Ganger D; Maddur H; Moore C; Hohlastos E; Katariya N; Caicedo JC; Kalyan A; Lewandowski RJ; Salem R
J Hepatol; 2020 Jun; 72(6):1151-1158. PubMed ID: 32145255
[TBL] [Abstract][Full Text] [Related]
3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
4. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
[No Abstract] [Full Text] [Related]
6. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
[TBL] [Abstract][Full Text] [Related]
7. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
8. Repeat Evaluation of Lung Shunt Fraction is Unnecessary: A Retrospective Observational Study of Successive Lung Shunt Fractions from Variable Arterial Distributions in Patients Undergoing Radioembolization of Primary and Secondary Liver Tumors.
Bulman JC; Zurkiya O; Wu V; Wehrenberg-Klee E; Palmer E; Chow D; Brook A; Ganguli S
J Vasc Interv Radiol; 2021 Mar; 32(3):412-418. PubMed ID: 33341340
[TBL] [Abstract][Full Text] [Related]
9. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
10. Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT.
Villalobos A; Cheng B; Wagstaff W; Sethi I; Bercu Z; Schuster DM; Brandon DC; Galt J; Kokabi N
J Vasc Interv Radiol; 2021 May; 32(5):752-760. PubMed ID: 33642158
[TBL] [Abstract][Full Text] [Related]
11. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
12. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
[TBL] [Abstract][Full Text] [Related]
13. Imaging Predictors of Elevated Lung Shunt Fraction in Patients Being Considered for Yttrium-90 Radioembolization.
Olorunsola OG; Kohi MP; Behr SC; Kolli PK; Taylor AG; Tong RT; LaBerge JM; Kerlan RK; Fidelman N
J Vasc Interv Radiol; 2015 Oct; 26(10):1472-8. PubMed ID: 26296737
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?
Elsayed M; Cheng B; Xing M; Sethi I; Brandon D; Schuster DM; Bercu Z; Galt J; Barron B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):254-260. PubMed ID: 33000319
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
16. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
17. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
Ali R; Riaz A; Gabr A; Abouchaleh N; Mora R; Al Asadi A; Caicedo JC; Abecassis M; Katariya N; Maddur H; Kulik L; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2195-2202. PubMed ID: 28812136
[TBL] [Abstract][Full Text] [Related]
19. Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma.
Gabr A; Ali R; Al Asadi A; Mora R; Mouli S; Riaz A; Salem R; Lewandowski RJ
Tech Vasc Interv Radiol; 2019 Jun; 22(2):93-99. PubMed ID: 31079717
[TBL] [Abstract][Full Text] [Related]
20. Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial.
Kokabi N; Webster LA; Elsayed M; Switchenko JM; Chen B; Brandon D; Galt J; Sethi I; Cristescu M; Kappadath SC; Schuster DM
J Vasc Interv Radiol; 2022 Dec; 33(12):1578-1587.e5. PubMed ID: 36075560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
